EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report

Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors....

Descripción completa

Detalles Bibliográficos
Autores principales: Takuma, Sho, Inoue, Yusuke, Karayama, Masato, Tsuchiya, Kazuo, Tsukui, Hiroe, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Inui, Naoki, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718492/
https://www.ncbi.nlm.nih.gov/pubmed/35005656
http://dx.doi.org/10.1016/j.jtocrr.2021.100264
_version_ 1784624739354935296
author Takuma, Sho
Inoue, Yusuke
Karayama, Masato
Tsuchiya, Kazuo
Tsukui, Hiroe
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
author_facet Takuma, Sho
Inoue, Yusuke
Karayama, Masato
Tsuchiya, Kazuo
Tsukui, Hiroe
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
author_sort Takuma, Sho
collection PubMed
description Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors. Here, we present a case of spontaneous transformation from EGFR-mutant LUAD with loss of p53 and RB to EGFR expression-positive SCLC and neuroendocrine-differentiated LUAD, which was successfully treated with osimertinib.
format Online
Article
Text
id pubmed-8718492
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87184922022-01-06 EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report Takuma, Sho Inoue, Yusuke Karayama, Masato Tsuchiya, Kazuo Tsukui, Hiroe Hozumi, Hironao Suzuki, Yuzo Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Suda, Takafumi JTO Clin Res Rep Case Report Lineage transformation from lung adenocarcinoma (LUAD) to SCLC is associated with resistance to EGFR tyrosine kinase inhibitors. In addition to loss of p53 and RB, transformed SCLCs are usually not dependent on EGFR signaling, which renders the tumors unresponsive to EGFR tyrosine kinase inhibitors. Here, we present a case of spontaneous transformation from EGFR-mutant LUAD with loss of p53 and RB to EGFR expression-positive SCLC and neuroendocrine-differentiated LUAD, which was successfully treated with osimertinib. Elsevier 2021-12-04 /pmc/articles/PMC8718492/ /pubmed/35005656 http://dx.doi.org/10.1016/j.jtocrr.2021.100264 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Takuma, Sho
Inoue, Yusuke
Karayama, Masato
Tsuchiya, Kazuo
Tsukui, Hiroe
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title_full EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title_fullStr EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title_full_unstemmed EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title_short EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
title_sort egfr-mutated lung adenocarcinoma successfully treated with osimertinib after spontaneous transformation to sclc and adenocarcinoma with neuroendocrine differentiation: case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718492/
https://www.ncbi.nlm.nih.gov/pubmed/35005656
http://dx.doi.org/10.1016/j.jtocrr.2021.100264
work_keys_str_mv AT takumasho egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT inoueyusuke egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT karayamamasato egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT tsuchiyakazuo egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT tsukuihiroe egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT hozumihironao egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT suzukiyuzo egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT furuhashikazuki egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT enomotonoriyuki egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT fujisawatomoyuki egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT nakamurayutaro egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT inuinaoki egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport
AT sudatakafumi egfrmutatedlungadenocarcinomasuccessfullytreatedwithosimertinibafterspontaneoustransformationtosclcandadenocarcinomawithneuroendocrinedifferentiationcasereport

Ejemplares similares